Virios Therapeutics CEO Greg Duncan to Present at the SHARE Series Investor Event on Monday, September 18, 2023

VIRIDelisted Stock  USD 3.95  0.00  0.00%   
Under 55% of Virios Therapeutics' investor base is interested to short. The analysis of current outlook of investing in Virios Therapeutics Llc suggests that many traders are impartial regarding Virios Therapeutics' prospects. Virios Therapeutics' investing sentiment shows overall attitude of investors towards Virios Therapeutics Llc.
  
ATLANTA, Sept. 12, 2023 -- Virios Therapeutics, Inc. , a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID , announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the SHARE Series Monday Management Update for investors on Monday, September 18, 2023, at 1100 am ET. This virtual event combine

Read at finance.yahoo.com
Yahoo News
  

Virios Therapeutics Fundamental Analysis

We analyze Virios Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Virios Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Virios Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Valuation

Current Valuation Comparative Analysis

Virios Therapeutics is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Virios Therapeutics Llc Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Virios Therapeutics stock to make a market-neutral strategy. Peer analysis of Virios Therapeutics could also be used in its relative valuation, which is a method of valuing Virios Therapeutics by comparing valuation metrics with similar companies.

Peers

Virios Therapeutics Related Equities

CYTOAltamira Therapeutics   7.50   
0%
90.0%
IMMXImmix Biopharma   7.11   
0%
85.0%
PHIOPhio Pharmaceuticals   3.03   
0%
36.0%
RNAZTranscode Therapeutics   2.94   
0%
35.0%
ZURAZura Bio   1.67   
0%
20.0%
REVBRevelation Biosciences   1.33   
0%
15.0%
ICULMF Acquisition   1.57   
18.0%
0%
SONNSonnet Biotherapeutics   2.28   
27.0%
0%
ZVSAZyVersa Therapeutics   3.60   
43.0%
0%
CNSPCns Pharmaceuticals   8.33   
100.0%
0%
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Consideration for investing in Virios Stock

If you are still planning to invest in Virios Therapeutics Llc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Virios Therapeutics' history and understand the potential risks before investing.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing